{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:20:50Z","timestamp":1776928850349,"version":"3.51.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["19VALO01"],"award-info":[{"award-number":["19VALO01"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human Epidermal Growth Factor Receptor 2 (HER2) is expressed in approximately 60%-70% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may contribute to androgen resistance. This case report describes a patient with HER2-expressing mCRPC who progressed on multiple lines of therapy and subsequently had a significant response to combination treatment with the HER2-targeting antibody-drug-conjugate (ADC) trastuzumab deruxtecan (T-DXd) and re-\u00adchallenge of abiraterone, despite having progressed on this prior. Unlike other HER2-expressing malignancies, HER2 overexpression in prostate cancer (PCa) occurs in the absence of HER2 mutations and amplifications and, as such, is not detected by next-\u00adgeneration sequencing. Therefore, identifying patients with mCRPC who could benefit from T-DXd necessitates HER2 testing by immunohistochemistry (IHC), a practice not routinely performed. As a result, T-DXd remains underutilized in patients with mCRPC, despite a tumor-agnostic approval for patients with advanced HER2-expressing (IHC 3+) solid tumors. This case highlights the potential of combining T-DXd with androgen receptor pathway inhibitors to overcome treatment resistance and underscores the importance of routine HER2 IHC testing in patients with advanced PCa.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf207","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:46:26Z","timestamp":1752162386000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-176X","authenticated-orcid":false,"given":"Rithika","family":"Rajendran","sequence":"first","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coen J","family":"Lap","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]},{"name":"Lombardi Comprehensive Cancer Center, Georgetown University , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Madapoosi","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Heiraty","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayez","family":"Estephan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, The George Washington University School of Medicine , Washington, DC 20052,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Hahn","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Poudel","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]},{"name":"Division of Hematology and Oncology, The George Washington University School of Medicine , Washington, DC 20052,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E","family":"Nava","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]},{"name":"Department of Pathology, The George Washington University School of Medicine , Washington, DC 20052,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Subrahmanyam","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-3055","authenticated-orcid":false,"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[{"name":"The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center , Washington, DC 20422,","place":["United States"]},{"name":"Division of Hematology and Oncology, The George Washington University School of Medicine , Washington, DC 20052,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025091815424014300_oyaf207-B1","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/0008-5472.CAN-09-0026","article-title":"Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2","volume":"69","author":"Cai","year":"2009","journal-title":"Cancer Res"},{"key":"2025091815424014300_oyaf207-B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4143\/crt.2012.44.1.50","article-title":"Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: immunohistochemical analysis and chromogenic in situ hybridization","volume":"44","author":"Baek","year":"2012","journal-title":"Cancer Res Treat"},{"key":"2025091815424014300_oyaf207-B3","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2025091815424014300_oyaf207-B4","author":"Wilkinson","year":"2024"},{"key":"2025091815424014300_oyaf207-B5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","article-title":"Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer","volume":"16","author":"Minner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025091815424014300_oyaf207-B6","doi-asserted-by":"crossref","first-page":"152219","DOI":"10.1016\/j.anndiagpath.2023.152219","article-title":"The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma","volume":"67","author":"Estephan","year":"2023","journal-title":"Ann Diagn Pathol"},{"key":"2025091815424014300_oyaf207-B7","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.3390\/cancers13236014","article-title":"Her2 expression in circulating tumor cells is associated with poor outcomes in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Maillet","year":"2021","journal-title":"Cancers"},{"key":"2025091815424014300_oyaf207-B8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091815424014300_oyaf207-B9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.7326\/ANNALS-24-01409","article-title":"Response of human epidermal growth factor receptor 2-Expressing prostate cancer to trastuzumab deruxtecan","volume":"177","author":"Lap","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025091815424014300_oyaf207-B10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025091815424014300_oyaf207-B11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/iju.15424","article-title":"Exploring androgen receptor signaling pathway in prostate cancer: a path to new discoveries","volume":"31","author":"Obinata","year":"2024","journal-title":"Int J Urol"},{"key":"2025091815424014300_oyaf207-B12","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.2147\/OTT.S245861","article-title":"Crosstalk between AR and Wnt signaling promotes castration-resistant prostate cancer growth","volume":"13","author":"Luo","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2025091815424014300_oyaf207-B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccell.2020.07.007","article-title":"Microenvironment-mediated resistance to anti-androgen therapy","volume":"38","author":"Orme","year":"2020","journal-title":"Cancer Cell"},{"key":"2025091815424014300_oyaf207-B14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06109-7","article-title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","volume":"187","author":"Wardley","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2025091815424014300_oyaf207-B15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/jcm13030734","article-title":"Prostate cancer liver metastasis: an ominous metastatic site in need of distinct management strategies","volume":"13","author":"Shiner","year":"2024","journal-title":"J Clin Med"},{"key":"2025091815424014300_oyaf207-B16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41585-024-00875-x","article-title":"From biology to the clinic\u2013exploring liver metastasis in prostate cancer","volume":"21","author":"Ni","year":"2024","journal-title":"Nat Rev Urol"},{"key":"2025091815424014300_oyaf207-B17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.14740\/wjon903w","article-title":"Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy","volume":"6","author":"Singh","year":"2015","journal-title":"World J Oncol"},{"key":"2025091815424014300_oyaf207-B18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/pros.24082","article-title":"Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer","volume":"81","author":"Iwamoto","year":"2021","journal-title":"Prostate"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf207\/63724048\/oyaf207.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf207\/63724048\/oyaf207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf207\/63724048\/oyaf207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:42:51Z","timestamp":1758224571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf207\/8196218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf207","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,10]]},"article-number":"oyaf207"}}